Defining the Value of Medicine in an Evidence-Based Healthcare M...( Thought-leaders Josh Ofman Steve ...),Health

Thought-leaders Josh Ofman, Steve Phurrough, Larry Kocot and Robert Seidman Headline Agenda at FDA/CMS Summit 2007

WASHINGTON, Nov. 26 /PRNewswire-USNewswire/ -- Value-based medicine has progressed beyond a topic of industry insider buzz to become a functional buying model adopted by public and private payers. Value isn't a new concept in the consumer marketplace, but what does it mean for buying and selling biopharmaceuticals? How is value calculated, and what are the variables? From setting prices to securing reimbursement, the valuation of treatments is tougher than ever to crack. And the stakes have never been higher with shrinking pipelines and tighter bottom lines. Getting the value calculation right can be the difference between success and failure of a new therapy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071126/DC08207 )

The FDA/CMS Summit, taking place December 6-7 in Washington, D.C., will feature key decision makers from government and industry to help biopharmaceutical executives understand how the value calculation is shifting, and what those changes mean for commercial success.

"Today, the value of a therapy is determined by more players than ever before, looking at more data than ever before. The threshold is a moving target for biopharmaceutical executives seeking reimbursement," said Cole Werble, editor-in-chief of The RPM Report, the conference organizer. "Learning what payers are looking at when making decisions early on can help industry come to market with successful products that are appropriately reimbursed. The FDA/CMS Summit provides leaders in industry key insight from reimbursement policy-makers who make purchasing and pricing decisions."

The FDA/CMS Summit provides health care executives with an exclusive opportunity to have face-to-face dialogues with top policymakers and executives. The Summit is aime
'/>"/>